Using exosomes to deliver anti-inflammatory treatments for preterm birth
Developing IL-10 encapsulated exosomes as novel therapeutics for spontaneous preterm birth
This study is exploring a new way to help prevent early births by using tiny particles called exosomes to deliver a special anti-inflammatory treatment, which could offer a better option for pregnant people at risk of preterm birth.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Med Br Galveston NIH-funded |
| Lab location | 1 site (Galveston, United States) |
| Project ID | NIH-10752691 on NIH RePORTER |
What this research studies
This research focuses on developing a new therapeutic approach to prevent spontaneous preterm birth (PTB) by using exosomes that encapsulate the anti-inflammatory cytokine IL-10. The study aims to enhance the delivery of this treatment across the placental barrier, addressing the limitations of current therapies that often fail to effectively reduce PTB rates. By engineering exosomes through electroporation, the researchers hope to improve pregnancy outcomes by balancing inflammation and supporting fetal development. Patients may benefit from a more effective treatment option that targets the underlying immune dysregulation associated with PTB.
Who could benefit from this research
Good fit: Ideal candidates for this research are pregnant individuals at risk of spontaneous preterm birth, particularly those experiencing inflammation or infections.
Not a fit: Patients who are not pregnant or those with conditions unrelated to preterm birth may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that significantly reduces the incidence of spontaneous preterm birth.
How similar studies have performed: While the use of exosomes for drug delivery is a growing field, this specific approach targeting preterm birth is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
Galveston, United States
- University of Texas Med Br Galveston — Galveston, United States (Active)
Researchers
- Principal investigator: Kammala, Ananth Kumar — University of Texas Med Br Galveston
- Study coordinator: Kammala, Ananth Kumar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.